Lexeo Therapeutics, Inc. (LXEO)
| Market Cap | 430.45M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -99.96M |
| Shares Out | 74.09M |
| EPS (ttm) | -1.86 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 438,089 |
| Open | 5.62 |
| Previous Close | 5.63 |
| Day's Range | 5.62 - 5.89 |
| 52-Week Range | 2.43 - 10.99 |
| Beta | 2.01 |
| Analysts | Strong Buy |
| Price Target | 18.44 (+217.38%) |
| Earnings Date | May 6, 2026 |
About LXEO
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical tr... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for LXEO stock is "Strong Buy." The 12-month stock price target is $18.44, which is an increase of 217.38% from the latest price.
News
Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, an...
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026 following Type B meeting; study initiation on track for 1H 2026 First CMC Development and Readiness Progr...
Lexeo Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Significant clinical progress was reported for both FA and PKP2 programs, with pivotal studies and regulatory updates planned for 2026. Manufacturing and commercial infrastructure are well established, and the company is financially positioned to support development through key milestones.
Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, to...
Lexeo Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
The session highlighted strong clinical progress in gene therapies for inherited cardiac diseases, with robust efficacy and safety data in both FA and PKP2-ACM programs. Key milestones include pivotal trial initiation for FA and major clinical updates for PKP2-ACM in late 2024.
Lexeo Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Lead gene therapy program for Friedreich's ataxia is advancing to a registrational study, with strong cardiac and neurologic benefits and a favorable safety profile. Early data in arrhythmogenic cardiomyopathy show significant efficacy, and regulatory updates are expected in early 2026.
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, tod...
Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, tod...
Lexeo Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
The conference showcased significant progress in cardiac gene therapy, with robust clinical data for Friedreich's ataxia and PKP2 arrhythmogenic cardiomyopathy, a strong safety profile, and a strategic focus on expanding the pipeline and partnerships.
Lexeo Therapeutics Transcript: Study result
Interim phase I-II data for LX2020 in PKP2-ACM show favorable safety, robust PKP2 expression, and clinically meaningful reductions in arrhythmia burden, especially in high-dose cohorts. No new serious adverse events or ICD shocks were observed, and further follow-up is ongoing.
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy
LX2020 generally well tolerated across ten participants with no clinically significant complement activation LX2020 transduction, transcription, and increased protein expression observed across parti...
Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
NEW YORK, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, tod...
Lexeo Therapeutics Transcript: Status Update
Arrhythmogenic cardiomyopathy due to PKP2 mutations presents high risk for arrhythmias and heart failure, with current management focused on arrhythmia control but lacking disease-modifying options. Gene therapy is viewed as a promising solution for most symptomatic patients, with high anticipated uptake and upcoming clinical data expected to inform its impact.
Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum
NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, tod...
Lexeo Therapeutics Transcript: Stifel 2025 Healthcare Conference
Two gene therapy programs are advancing, with strong efficacy and safety data in Friedreich's ataxia and PKP2 cardiomyopathy. FDA alignment may allow smaller pivotal studies, and commercial strategies target early adopters with scalable manufacturing. Cash runway extends into 2028.
Lexeo Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Two clinical-stage programs are advancing, with Friedreich's ataxia entering a pivotal study in 2026 and PKP2 data expected in January. FDA alignment may accelerate approval, and robust efficacy and safety data support broad patient eligibility. Pricing will reflect clinical benefit, and manufacturing comparability is on track.
Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights
FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier co-primary endpoint assessment, to support a Biologics License Application FDA approved ...
Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters' Option to Purchase Additional Shares in the Public Offering
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) (“Lexeo”), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular dis...
Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement
NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, tod...
Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) (the “Lexeo”), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular...
Lexeo Therapeutics Transcript: H. C. Wainwright Genetic Medicines Virtual Conference
Significant progress was reported in gene therapy programs for Friedreich's ataxia and arrhythmogenic cardiomyopathy, with strong clinical data and regulatory momentum. The lead therapy showed dramatic cardiac and neurologic improvements, and the FDA has agreed to an expedited approval path.
Lexeo Therapeutics Transcript: Study Update
FDA supports pooling phase I/II and pivotal data for LX2006, potentially accelerating approval. Interim results show robust, dose-dependent improvements in cardiac and neurologic outcomes, with a favorable safety profile and durable benefits.
Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy
U.S. Food and Drug Administration (FDA) open to pooling data from ongoing Phase I/II studies of LX2006 with pivotal data to support a Biologics License Application (BLA) for Accelerated Approval Inter...
Lexeo Therapeutics Transcript: Stifel Virtual Cardiometabolic Forum
Gene therapy programs for Friedreich's ataxia and arrhythmogenic cardiomyopathy are advancing, with strong Phase I data, FDA-aligned endpoints, and a favorable safety profile. Commercial focus will start with high-risk patients, and a recent capital raise secures funding into 2028.
Lexeo Therapeutics Transcript: Baird Global Healthcare Conference 2025
The company is advancing gene therapies for cardiac and neurologic diseases, with lead programs in Friedreich’s Ataxia and arrhythmogenic cardiomyopathy. Early clinical data show strong efficacy and safety, with pivotal studies planned for 2026 and a solid financial runway into 2028.